BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review
BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
BioCryst Pharmaceuticals Inc (BioCryst) designs, optimizes and develops small molecule drugs that block key enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary Angioedemaon. It integrates disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consists of Rapivab, Alpivab, Rapiacta and Peramiflu for the treatment of Influenza. The company has strategic partnerships with corporate and academic institutes and has research operations in Birmingham, Alabama. BioCryst is headquartered in Durham, North Carolina, the US.
BioCryst Pharmaceuticals Inc Key Recent Developments
Feb 25,2021: BioCryst reports fourth quarter and full year 2020 financial results and upcoming key milestones
Feb 11,2021: BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
Nov 13,2020: BioCryst presents new data highlighting burden of therapy with current injectable prophylaxis medication for HAE
Aug 06,2020: BioCryst reports second quarter 2020 financial results and upcoming key milestones
Jun 06,2020: Hereditary angioedema patients report breakthrough attacks on current injectable/infused prophylaxis medication
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
BioCryst Pharmaceuticals Inc (BioCryst) designs, optimizes and develops small molecule drugs that block key enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary Angioedemaon. It integrates disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consists of Rapivab, Alpivab, Rapiacta and Peramiflu for the treatment of Influenza. The company has strategic partnerships with corporate and academic institutes and has research operations in Birmingham, Alabama. BioCryst is headquartered in Durham, North Carolina, the US.
BioCryst Pharmaceuticals Inc Key Recent Developments
Feb 25,2021: BioCryst reports fourth quarter and full year 2020 financial results and upcoming key milestones
Feb 11,2021: BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
Nov 13,2020: BioCryst presents new data highlighting burden of therapy with current injectable prophylaxis medication for HAE
Aug 06,2020: BioCryst reports second quarter 2020 financial results and upcoming key milestones
Jun 06,2020: Hereditary angioedema patients report breakthrough attacks on current injectable/infused prophylaxis medication
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
BioCryst Pharmaceuticals Inc - Key Facts
BioCryst Pharmaceuticals Inc - Key Employees
BioCryst Pharmaceuticals Inc - Key Employee Biographies
BioCryst Pharmaceuticals Inc - Major Products and Services
BioCryst Pharmaceuticals Inc - History
BioCryst Pharmaceuticals Inc - Company Statement
BioCryst Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
BioCryst Pharmaceuticals Inc - Business Description
BioCryst Pharmaceuticals Inc - Corporate Strategy
BioCryst Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
BioCryst Pharmaceuticals Inc - Strengths
BioCryst Pharmaceuticals Inc - Weaknesses
BioCryst Pharmaceuticals Inc - Opportunities
BioCryst Pharmaceuticals Inc - Threats
BioCryst Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 25, 2021: BioCryst reports fourth quarter and full year 2020 financial results and upcoming key milestones
Feb 11, 2021: BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February
Nov 13, 2020: BioCryst presents new data highlighting burden of therapy with current injectable prophylaxis medication for HAE
Aug 06, 2020: BioCryst reports second quarter 2020 financial results and upcoming key milestones
Jun 06, 2020: Hereditary angioedema patients report breakthrough attacks on current injectable/infused prophylaxis medication
May 15, 2020: BioCryst celebrates HAE patients with HAE Global Walk
May 06, 2020: BioCryst reports first quarter 2020 financial results and upcoming key milestones
Apr 02, 2020: BioCryst appoints Anthony Doyle Chief Financial Officer
Mar 05, 2020: BioCryst reports fourth quarter and full year 2019 financial results and upcoming key milestones
Feb 25, 2020: BioCryst appoints Alan G. Levin to Board of Directors
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
BioCryst Pharmaceuticals Inc - Key Facts
BioCryst Pharmaceuticals Inc - Key Employees
BioCryst Pharmaceuticals Inc - Key Employee Biographies
BioCryst Pharmaceuticals Inc - Major Products and Services
BioCryst Pharmaceuticals Inc - History
BioCryst Pharmaceuticals Inc - Company Statement
BioCryst Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
BioCryst Pharmaceuticals Inc - Business Description
BioCryst Pharmaceuticals Inc - Corporate Strategy
BioCryst Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
BioCryst Pharmaceuticals Inc - Strengths
BioCryst Pharmaceuticals Inc - Weaknesses
BioCryst Pharmaceuticals Inc - Opportunities
BioCryst Pharmaceuticals Inc - Threats
BioCryst Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 25, 2021: BioCryst reports fourth quarter and full year 2020 financial results and upcoming key milestones
Feb 11, 2021: BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February
Nov 13, 2020: BioCryst presents new data highlighting burden of therapy with current injectable prophylaxis medication for HAE
Aug 06, 2020: BioCryst reports second quarter 2020 financial results and upcoming key milestones
Jun 06, 2020: Hereditary angioedema patients report breakthrough attacks on current injectable/infused prophylaxis medication
May 15, 2020: BioCryst celebrates HAE patients with HAE Global Walk
May 06, 2020: BioCryst reports first quarter 2020 financial results and upcoming key milestones
Apr 02, 2020: BioCryst appoints Anthony Doyle Chief Financial Officer
Mar 05, 2020: BioCryst reports fourth quarter and full year 2019 financial results and upcoming key milestones
Feb 25, 2020: BioCryst appoints Alan G. Levin to Board of Directors
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
BioCryst Pharmaceuticals Inc, Key Facts
BioCryst Pharmaceuticals Inc, Key Employees
BioCryst Pharmaceuticals Inc, Key Employee Biographies
BioCryst Pharmaceuticals Inc, Major Products and Services
BioCryst Pharmaceuticals Inc, History
BioCryst Pharmaceuticals Inc, Other Locations
BioCryst Pharmaceuticals Inc, Subsidiaries
BioCryst Pharmaceuticals Inc, Key Competitors
BioCryst Pharmaceuticals Inc, Ratios based on current share price
BioCryst Pharmaceuticals Inc, Annual Ratios
BioCryst Pharmaceuticals Inc, Annual Ratios (Cont...1)
BioCryst Pharmaceuticals Inc, Interim Ratios
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
BioCryst Pharmaceuticals Inc, Key Facts
BioCryst Pharmaceuticals Inc, Key Employees
BioCryst Pharmaceuticals Inc, Key Employee Biographies
BioCryst Pharmaceuticals Inc, Major Products and Services
BioCryst Pharmaceuticals Inc, History
BioCryst Pharmaceuticals Inc, Other Locations
BioCryst Pharmaceuticals Inc, Subsidiaries
BioCryst Pharmaceuticals Inc, Key Competitors
BioCryst Pharmaceuticals Inc, Ratios based on current share price
BioCryst Pharmaceuticals Inc, Annual Ratios
BioCryst Pharmaceuticals Inc, Annual Ratios (Cont...1)
BioCryst Pharmaceuticals Inc, Interim Ratios
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
BioCryst Pharmaceuticals Inc, Performance Chart (2016 - 2020)
BioCryst Pharmaceuticals Inc, Ratio Charts
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Performance Chart (2016 - 2020)
BioCryst Pharmaceuticals Inc, Ratio Charts
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021